Investment area

Bioindustrial Investments

Growth Investments


North America

Date of investment

October 2021

Biomilq is unlocking human potential with breakthrough mammary biotechnology, with a new option for supplemental feeding—one that’s as close to breastmilk as possible and cultivated under safe conditions using their first-of-its-kind technology.

Visit site


Kartik Dharmadhikari


Departments: Growth Investments, Novo Holdings Equity US Inc., Bioindustrial Investments

Kartik focuses on investments across industrial biotechnology and is based in our San Francisco office.

Prior to joining Novo Holdings, Kartik served as Associate Partner at McKinsey & Co. working with clients across healthcare, agriculture, chemicals and consumer products on biotechnology strategy and operational topics. Previous to that, Kartik worked at Novozymes in a variety of business building and corporate development roles in both Denmark and the U.S.

Kartik holds an MBA from Columbia Business School and a BA from Northwestern University.